Brief: Monte Rosa Therapeutics Announces Q1 Results
11/05/2023 12:49
May 11 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O :
* MONTE ROSA THERAPEUTICS ANNOUNCES FIRST QUARTER 2023
FINANCIAL
RESULTS AND PROVIDES CORPORATE UPDATE
* MONTE ROSA THERAPEUTICS INC - ON TRACK TO PRESENT INITIAL
DATA
FROM PHASE 1/2 CLINICAL TRIAL OF MRT-2359 IN MYC-DRIVEN SOLID
TUMORS IN H2 2023
* MONTE ROSA THERAPEUTICS INC - CASH RUNWAY INTO 2025
SUPPORTS
OPERATIONS & ADVANCEMENT OF PIPELINE OF NOVEL MOLECULAR GLUE
DEGRADERS TO KEY INFLECTION POINTS
* MONTE ROSA THERAPEUTICS INC- QTRLY LOSS PER SHARE $0.65
Source text for Eikon: ID:nGNX1fbdTV
Further company coverage: GLUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million